StemCell Therapy

Honolulu, Hawaii A surgical nurse with the functional specialty team in the 322nd Civil Affairs Brigade, 9th Mission Support Command, began her voyage on the U.S. Coast Guard Cutter Joseph Gerczak, in order to provide advanced medical support and ensure the health and safety of all crew members while the Coast Guard conducts Hawaiian Island patrol.1st Lt. Kayla Kight, a 12-year veteran from Palm Bay, Florida, comes with an extensive background to include medical telemetry, oncology, acute care, family medicine, internal and preventative medicine. Shes also the first nurse to graduate from the 25th Infantry Division Jungle Operations Course.My courses, experiences and knowledge have set me up for success to provide adequate support for this mission, said Kight. I have been preparing individually for this mission by recently recertifying my licensures in Basic Life Savers, Advanced Cardio Life Saver, Pediatric Life Saver, and the use of the AED.Kight will be the only medical support officer on board from the Army Reserve in support of the U.S. Coast Guard.Its kind of a test run for, hopefully, future operations where we push out a little further south, toward American Samoa and other Pacific regions, said 1st Lt. Casey Rude, Executive Officer on board the Joseph Gerczak, part of the Sand Island Coast Guard Station in Honolulu, Hawaii. She will provide that extra advanced medical support on our platform 154-foot vessel. There are no health service technicians from the Coast Guard so this will allow us to have that advanced medical care for those longer trips.In addition to providing important medical care, 1st Lt. Kight will also have additional tasks on board.Shes going to provide some advanced training to the crew with AEDs and other life saving techniques while seeing the day in the life of the Coast Guard as well, said Rude. Well run her through some of our drills and do some of the things we do.This is the first time the 322nd Civil Affairs Brigade is sending personnel for medical support with the Coast Guard.This is the first mission of its kind for us and in this region, said Rude. The connection was done through our district office. We want to strengthen the partnership with the Army and allow for potential future operations.Kight is grateful for this experience, saying, I am thankful to my leadership for giving me this great opportunity, this is my first time participating in a mission like this. Ultimately, I am happy to give reassurance and trust to the team that I am competent and an expert in my skills.

Excerpt from:
Partnership in the Pacific Army Reserve Nurse Provides Medical Care for Coast Guard Unit - United States Army

BASKING RIDGE, N.J., July 09, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executive Officer, will participate in three upcoming investor conferences:

Maxim Group/M-Vest COVID-19 Virtual Conference Series: Re-Engaging Medical Practices in an Era of COVID-19Format: panel discussionDate: Thursday, July 16Panel 2, Cant Touch This! Time for These Devices to Shine!Time: 12:30pm 1:45pm ET

To access the panel discussion, please RSVP HERE

Zooming with LD MicroFormat: corporate presentation followed by 1x1 virtual investor meetingsDate: Tuesday, July 21Time: 8:00am 8:40am PT

Investors can register for the presentation HERE.

Canaccord Genuity 40th Annual Growth ConferenceFormat: 1x1 virtual investor meetingsDate: Tuesday, August 11

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The companys initial targets are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit http://www.electrocore.com.

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patients neck over the vagus nerve, gammaCore stimulates the nerves afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua), Bronchoconstriction and Medication Overuse Headache in adults.

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Investors:

Hans VitzthumLifeSci Advisors617-430-7578hans@lifesciadvisors.com

or

Media Contact:

Jackie DorskyelectroCore 973-290-0097jackie.dorsky@electrocore.com

Continue reading here:
electroCore to Participate in Three Upcoming Virtual Investor Conferences - Yahoo Finance

With more than 6,300 confirmed cases of COVID-19 in South Dakota, theres a chance you may know someone who has been impacted by the disease. But theres also a good chance you dont. So, South Dakota Farmers Union reached out to nurses who not only know rural community members impacted by COVID-19, but they also have some suggestions on how to protect you and those you love from this highly contagious virus.

DONNI VAN SANTEN, SIOUX FALLS

Theres a photo of a flight nurse walking toward the Avera helicopter hanging on the wall where Donni Van Santen and the other members of the flight team prepare to provide emergency care across the state and region via helicopter and airplane.

It says, I heard the voice of the Lord saying, whom shall I send, who will go for them? I said, here I am Lord, send me, shares Van Santen. If we ever forget why we do what we do, we are quickly reminded. I love being able to help save lives and be the light to brighten someones possibly worst day.

And as the base supervisor in Sioux Falls for Careflight, the registered nurse says she also appreciates the fact that no two flights are the same. I enjoy the autonomy and variety of flight nursing. On a typical flight, it is myself and a partner. We make decisions together just the two of us.

Because of the nature of emergency care, Van Santen says once they land, she and her partner typically rush to the patient. It is in our blood and our nature to rush into the hospital room or scene of an accident because if we are called, things are really bad, and they need our help. With COVID, they make sure to slow down long enough to put on appropriate protective gear first.

Her fast-paced workdays do differ a bit from the work underway on her familys Blue Mound Dairy Farm near Luverne, Minn. Also essential workers, her husband, Brad and his brothers are the third generation to operate the dairy. They milk around 1,000 cows three times a day.

What is your advice to farmers like your husband and brothers-in-law? Dont let your guard down. If you get sick, and you cant work for two weeks, what does that look like on your farm?

Just because COVID may not be in our community, or you are hearing less about it, does not mean it is any less serious. Wear your mask. Follow CDC guidelines. Practice social distancing and stay home if you are sick.

If wearing a mask or practicing social distancing when you are in a public space is not something you feel comfortable doing for yourself, do it for those your care about family, neighbors and friends. It is possible to spread COVID and not know you have the virus.

Because of COVID, I cancelled my annual physical. Is it safe to go to the doctor for preventative care? Yes. Special measures have been put into place in hospitals and clinics to protect patients. And although some procedures, like colonoscopies and mammograms were put on hold for a period of time, you can schedule them now.

One more thought. Its OK to not be OK. Unfortunately, we have seen quite a rise in suicide rates. This is a scary time. If you are struggling with what is going on with the ag economy and additional stress from COVID, there is help. Please reach out to the Farm & Rural Stress Hotline: 1-800-691-4336.

NATALIE BARTEL, WESSINGTON SPRINGS

When Natalie Bartel first heard about the COVID-19 pandemic in China, her first thoughts were, I hope it doesnt get here.

Unfortunately, it did. To date, there have been 40 cases in Jerauld County. Some have been severe enough to land in the rural, at Avera WesKota Memorial Hospital.

At first Bartel was nervous. However, the hospital protocols and personal protective equipment eased her fears. If a patient is positive, or possibly positive, for COVID, they stay in a negative pressure room so that the virus doesnt escape into the rest of the hospital. Nurses who care for COVID patients are provided with a special forced-air hood and other protective equipment.

I think were doing an excellent job taking care of our patients in our little hospital, but also we are vigilant about protecting the staff, she explains.

Patient care is what Bartel appreciates about her work as a nurse in a rural hospital. I enjoy taking care of the people in my community. I know them and I care about them.

Nursing is the career Bartel chose because she knew she wanted to live and work in a rural community and she knew there would always be a need for healthcare workers. She grew up on a farm and married a farmer. Together with her husband, Josh, the couple run a cow/calf herd and grow corn and soybeans. Natalie says nursing is also a career that provides her with the flexibility she needs with three young children and a husband working long, farmer hours.

I work about five night shifts a month, so it works out pretty well because I can take a nap in the afternoon and on those days Josh can typically get home to take care of the girls when I need to leave for work a little after 6 p.m.

Whats your advice? Its important when you are out in the community that you practice social distancing. If everyone would wear a mask, I think that we would see a reduction in the number of cases. I know its not the cool thing to do and its not convenient. But this isnt forever. This too shall pass.

If you run errands, keep hand sanitizer in your vehicle so you can clean your hands before you go home.

Washing hands is a really simple thing to do. But it can make all the difference.

What if Im young and healthy, do I still need to be careful? You need to think about the people youre coming in contact with. So, it might not just be you. It might be your elderly mom who has heart disease, or even a neighbors child that has asthma COVID could really affect them in detrimental ways, so you have to consider your loved ones too and make sure that youre protecting them as well as protecting yourself.

HANNAH SUMPTION, ABERDEEN

The other day, Hannah Sumption, a licensed practical nurse, was having a conversation with a patient about the pandemic and the patient said, I am OK if the Lord gives it to me, if that is what happens. In the meantime, he has also given me all the supplies and information I need to take care and not get it.

Educating patients on how to protect themselves is something Sumption takes seriously and enjoys.

Especially now with the pandemic, there is fear, I like to educate people, because fear can take over the mind so quick and cause people to jump to conclusions, explains Sumption, who works for Sanford Aberdeen Clinic in the Internal Medicine Department. If people are educated and know about the disease, they will know how to protect themselves. Also, with all the media attention, people dont know what to believe to make the right decision. As a nurse, patients know the information we give them comes from a credible source.

Educating others was always part of Sumptions career plan. She just thought she would do it as an agriculture communicator. Growing up on my familys farm, I love agriculture and I want to tell everyone about what we do, she says of her familys Frederick crop and livestock operation.

As she began to explore career options her senior year of high school, her sister, Haileys career as a nurse, inspired her to look at pursuing a degree in the medical field. She visited Mitchell Technical Institute and met with the nursing instructors. Her decision was solidified when she received a full ride, Build Dakota scholarship. It really helped my decision that I got my LPN degree paid for and knowing I would always have a stable job. Nurses are always needed in rural areas.

Sumption was only six months into her first job when the pandemic broke. At first, like many of her patients, she was nervous. The most nerve-wracking thing about it is what we dont know about it.

Today, what she does know about the virus does not inflict fear. It empowers her to protect herself, the patients she serves and the family she loves. In addition to the usual clinic work checking vitals, assisting with procedures and giving immunizations and other shots, Sumption is also a member of the COVID testing team. As she swabs patients, she wears a disposable gown, glove, mask and face shield.

Even when she is not at work, Sumptionis careful. She avoids congested shopping areas, washes her hands frequently and does not touch her cell phone while she is grocery shopping or running other errands.

I am careful because we are a close-knit family and I am most afraid of giving it to my grandparents, because statistically, they cant fight it as well as the rest of us can, Sumption explains. My advice to my family is, dont freak out about it. Take precautions and wash your hands.

What other advice do you have to share? Even when you get together with family, be smart about it. Dont be hugging on people. Wash your hands. Maybe, dont use public restrooms. Being in the open air helps. If you can have an outside gathering that is best and keep the numbers down.

What about going to bars and restaurants? I get if you want to go to the local bar because you have not been there in a while. But keep your distance. Wash your hands. I would not recommend bar hopping or drinking too much because alcohol suppresses the immune system.

MARY JO NEMEC, PIERRE

As a high school senior, Mary Jo Nemec ran into one of her friends filling out an application to attend Pierre School of Practical Nursing. Because she didnt have any solid plans after graduation, she decided to follow her friends lead.

Funny thing is, I went and finished, and she ended up not going.

Although happenstance is how she began her nursing career, Mary Jo Nemec has been very intentional about its progression. Throughout her 40-year career, she has periodically returned to school to pursue advanced nursing degrees. Today, she is a nurse practitioner and works for South Dakota Urban Indian Health.

I enjoy working with people. I have never been attracted to management positions. I just want to do patient care and work one-on-one with patients.

Toward the beginning of the outbreak, Nemec actually thinks she contracted the virus, but there was not any testing to confirm. So, she quarantined for a month. I had a sore throat, but I did not have strep. I had a fever, felt short of breath, fatigue and body aches.

Now back in the clinic, she says personal protective gear makes her feel safe to interact with patients and continue doing the work she loves.

When she is not with her patients, she continues to wear a mask whenever she is around anyone other than her husband, Nick, who farms near Holabird.

We got together with our children for Mothers Day. We ate outside and sat around 6-feet apart with our masks on and visited, she explains.

What are your recommendations for farm and ranch families? Wear a mask wherever you go. Wash your hands. Be careful where you go. Look around. If someone is walking toward you without a mask, stay away from them as much as possible. And I would not go into a big crowd.

What about getting together with friends and family? Social distancing outside is fairly safe. Wear your mask. Be more than 6 feet apart. And limit your contact with people.

Read the rest here:
Neighbors: What Nurses Connected To Ag Have To Say About COVID - Yankton Daily Press

Close your eyes, breathe in deeply and exhaleThe Graf Center for Integrative Medicine has re-opened with enhanced safety measures.

Now, more than ever, we can all use some integrative medicine. Give yourself the break you need and focus on your wellness. Englewood Health is committed to your safety. Weve implemented important new procedures and precautions at the Graf Center for Integrative Medicine to ensure your safety and comfort and reduce your stress.

The Graf Center offers evidence-based care in a spa-like setting. Now, booking an appointment is easier than ever. Well take pre-payment over the phone and email you any forms to complete, prior to your appointment. When you arrive at the Graf Center, youll wait in your car (instead of a waiting room) until were ready for your appointment. Then, well call you on your cell phone and invite you to come inside.

Our therapists will greet you at the front desk and immediately take you to a treatment room. Hand sanitizer and wipes are available in your room and youll be able to place your personal belongings in a clean plastic bag. Masks and gloves are worn by our staff and available for patients, as needed. After each patient, we immediately change and remove the linens, then use enhanced cleaning procedures to sanitize the room before the next patient. Weve also extended the time between appointments allowing ample space to limit exposure and ensure thorough cleaning. Follow up appointments are conveniently booked by phone.

Services available include:

Take the time to de-stress. Make an appointment today by calling the Graf Center for Integrative Medicine at 201-608-2377.

The Graf Center for Integrative Medicine is Englewood Hospitals wellness center. Our mission is to partner with patients and our community on the path to health and well-being.

Graf Center services promote recovery and empower you to live a healthy lifestyle. We offer:

Weve designed many services for people facing an illness. But anyone can benefit from integrative medicine. If youre looking to make positive lifestyle changes for your physical, mental, and social well-being, we invite you to:

Also, like us on Facebook and Instagram or join our email list to get updates and health and wellness tips.

Integrative medicine combines traditional and complementary therapies. Our coordinated approach supports healing and addresses all aspects of health. Well work with you to tailor a plan to help:

Integrative medicine refers to the use of conventional and complementary therapies together in a coordinated and evidence-based way, to facilitate the healing process. In integrative medicine, we consider the patient as a whole person and develop a plan for healing that addresses all aspects of health.

Dr. Tracy Scheller, medical director of integrative medicine

When you enter the Graf Center for Integrative Medicine, youll be struck by its spa-like feel (take a photo tour). Though it doesnt feel like a hospital, we are fully part of Englewood Health. Our team members are all licensed or certified, and we are overseen by a medical doctor. So you can trust us for safe, evidence-based care.

Unlike alternative medicine (a non-mainstream approach used instead of conventional medicine), we may use non-mainstream therapies together with conventional medicine. If you seek Graf Center services while being treated fora health issue, we will work with your own doctor to help tailor a treatment plan. Above all, your safety always comes first.

Original post:
Graf Center for Integrative Medicine | Englewood Health

Jul 9, 2020 11:00 AM ET

iCrowd Newswire Jul 9, 2020

Laurel, Md. The Natural Care Center (NCC) at Maryland University of Integrative Health is now offering some free telehealth services amid the COVID-19 pandemic. The NCC is equipped with wellness practitioners and supervised student practitioners all of whom are focused on holistic, relationship-focused health and wellness.

With digital communication becoming the new normal, MUIH is prepared to provide virtual services. Clients can work with our wellness practitioners for Acupuncture, Naturopathic Medicine, Nutrition, and Yoga Therapy for a small fee. Supervised student practitioners will provide Acupuncture, Chinese Herbal Medicine, and Yoga Therapy services free of charge.

Using their holistic foundation and principles, MUIHs student practitioners as well as the wellness practitioners are equipped with the knowledge to virtually instruct their clients through traditional physical contact wellness activities such as Acupuncture. While the needles are part of Oriental Medicine, there are many other aspects that include nutritional recommendations, meditation practices, movement practices, and lifestyle recommendations that accompany them.

The acupuncturist can also instruct the patient in self-acupressure with specific points to enhance the experience based on the Oriental Medicine diagnosis for that individual. The rapport between patient and practitioner also has a healing effect, using words as needles.

The NCC is ready and able to serve as a health and wellness resource during these times. We are committed to providing the community with uninterrupted care, holistic health tools, and relationship-centered attention to our clients, said Michelle McNear, Ph.D., Director of the Natural Care Center at MUIH.

During these fast-paced and uncertain times, MUIH remains committed to our mission of providing our community with relationship-focused, holistic health, and wellness solutions. Our students and practitioners are well-equipped to handle this remote treatment model while providing the same level of care and comfort that has made us one of the leading institutions for integrative health, said President and CEO, Marc Levin.

For those individuals interested in telehealth services provided by the NCC at MUIH, please call 410-888-9048 ext. 6614 or email at [emailprotected].

About Maryland University of Integrative Health (MUIH)

Maryland University of Integrative Health (MUIH) is a leading academic institution focused on the study and practice of integrative health and wellness and one of the few universities in the U.S. dedicated solely to such practices. Deeply rooted in a holistic philosophy, its model for integrative health and wellness is grounded in whole-person, relationship-centered, evidence-informed care.

Since 1974, MUIH has been a values-driven community educating practitioners and professionals to become future health and wellness leaders through transformative programs grounded in traditional wisdom and contemporary science. MUIH has more than 20 progressive, graduate degree programs in a wide range of disciplines, offered on-campus and online.

In the on-campus Natural Care Center and community outreach settings, MUIH provides compassionate and affordable healthcare from student interns and professional practitioners, which delivers more than 20,000 clinical treatments and consultations each year. For more information visit http://www.muih.edu.

Kionne S. Johnson Communications Manager [emailprotected]

Keywords:COVID-19, Pandemic, Health, Healthcare, Wellness, Therapy, Acupuncture, Health Education, Telehealth

Here is the original post:
Maryland University of Integrative Healths Natural Care Center is providing telehealth services amid the COVID-19 pandemic. - Reported Times

LOS ANGELES, United States: QY Research has recently published a report, titled Global Genomic Biomarker Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Genomic Biomarker market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Genomic Biomarker market include: Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1605804/global-genomic-biomarker-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Genomic Biomarker market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Genomic Biomarker Market Segment By Type:

Protein MarkerNucleic Acid MarkerOther

Global Genomic Biomarker Market Segment By Application:

HospitalsDiagnostic and research laboratories Global Genomic Biomarker

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Genomic Biomarker market.

Key companies operating in the global Genomic Biomarker market include Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1605804/global-genomic-biomarker-market

TOC

1 Market Overview of Genomic Biomarker1.1 Genomic Biomarker Market Overview1.1.1 Genomic Biomarker Product Scope1.1.2 Market Status and Outlook1.2 Global Genomic Biomarker Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Genomic Biomarker Market Size by Region (2015-2026)1.4 Global Genomic Biomarker Historic Market Size by Region (2015-2020)1.5 Global Genomic Biomarker Market Size Forecast by Region (2021-2026)1.6 Key Regions, Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.1 North America Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.2 Europe Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.4 Latin America Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Genomic Biomarker Market Size YoY Growth (2015-2026) 2 Genomic Biomarker Market Overview by Type2.1 Global Genomic Biomarker Market Size by Type: 2015 VS 2020 VS 20262.2 Global Genomic Biomarker Historic Market Size by Type (2015-2020)2.3 Global Genomic Biomarker Forecasted Market Size by Type (2021-2026)2.4 Protein Marker2.5 Nucleic Acid Marker2.6 Other 3 Genomic Biomarker Market Overview by Application3.1 Global Genomic Biomarker Market Size by Application: 2015 VS 2020 VS 20263.2 Global Genomic Biomarker Historic Market Size by Application (2015-2020)3.3 Global Genomic Biomarker Forecasted Market Size by Application (2021-2026)3.4 Hospitals3.5 Diagnostic and research laboratories 4 Global Genomic Biomarker Competition Analysis by Players4.1 Global Genomic Biomarker Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Genomic Biomarker as of 2019)4.3 Date of Key Manufacturers Enter into Genomic Biomarker Market4.4 Global Top Players Genomic Biomarker Headquarters and Area Served4.5 Key Players Genomic Biomarker Product Solution and Service4.6 Competitive Status4.6.1 Genomic Biomarker Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Bio-Rad5.1.1 Bio-Rad Profile5.1.2 Bio-Rad Main Business5.1.3 Bio-Rad Products, Services and Solutions5.1.4 Bio-Rad Revenue (US$ Million) & (2015-2020)5.1.5 Bio-Rad Recent Developments5.2 Beckman Coulter5.2.1 Beckman Coulter Profile5.2.2 Beckman Coulter Main Business and Companys Total Revenue5.2.3 Beckman Coulter Products, Services and Solutions5.2.4 Beckman Coulter Revenue (US$ Million) (2015-2020)5.2.5 Beckman Coulter Recent Development and Reaction to Covid-195.3 Myriad Genetics5.5.1 Myriad Genetics Profile5.3.2 Myriad Genetics Main Business5.3.3 Myriad Genetics Products, Services and Solutions5.3.4 Myriad Genetics Revenue (US$ Million) & (2015-2020)5.3.5 Thermo Fisher Scientific Recent Developments5.4 Thermo Fisher Scientific5.4.1 Thermo Fisher Scientific Profile5.4.2 Thermo Fisher Scientific Main Business5.4.3 Thermo Fisher Scientific Products, Services and Solutions5.4.4 Thermo Fisher Scientific Revenue (US$ Million) & (2015-2020)5.4.5 Thermo Fisher Scientific Recent Developments5.5 Roche5.5.1 Roche Profile5.5.2 Roche Main Business5.5.3 Roche Products, Services and Solutions5.5.4 Roche Revenue (US$ Million) & (2015-2020)5.5.5 Roche Recent Developments5.6 QIAGEN5.6.1 QIAGEN Profile5.6.2 QIAGEN Main Business5.6.3 QIAGEN Products, Services and Solutions5.6.4 QIAGEN Revenue (US$ Million) & (2015-2020)5.6.5 QIAGEN Recent Developments5.7 Epigenomics5.7.1 Epigenomics Profile5.7.2 Epigenomics Main Business and Companys Total Revenue5.7.3 Epigenomics Products, Services and Solutions5.7.4 Epigenomics Revenue (US$ Million) (2015-2020)5.7.5 Epigenomics Recent Development and Reaction to Covid-195.8 Almac5.8.1 Almac Profile5.8.2 Almac Main Business5.8.3 Almac Products, Services and Solutions5.8.4 Almac Revenue (US$ Million) & (2015-2020)5.8.5 Almac Recent Developments5.9 Pfizer5.9.1 Pfizer Profile5.9.2 Pfizer Main Business5.9.3 Pfizer Products, Services and Solutions5.9.4 Pfizer Revenue (US$ Million) & (2015-2020)5.9.5 Pfizer Recent Developments5.10 Human Longevity5.10.1 Human Longevity Profile5.10.2 Human Longevity Main Business5.10.3 Human Longevity Products, Services and Solutions5.10.4 Human Longevity Revenue (US$ Million) & (2015-2020)5.10.5 Human Longevity Recent Developments5.11 ValiRx5.11.1 ValiRx Profile5.11.2 ValiRx Main Business5.11.3 ValiRx Products, Services and Solutions5.11.4 ValiRx Revenue (US$ Million) & (2015-2020)5.11.5 ValiRx Recent Developments5.12 Personalis5.12.1 Personalis Profile5.12.2 Personalis Main Business5.12.3 Personalis Products, Services and Solutions5.12.4 Personalis Revenue (US$ Million) & (2015-2020)5.12.5 Personalis Recent Developments5.13 Eagle Genomics5.13.1 Eagle Genomics Profile5.13.2 Eagle Genomics Main Business5.13.3 Eagle Genomics Products, Services and Solutions5.13.4 Eagle Genomics Revenue (US$ Million) & (2015-2020)5.13.5 Eagle Genomics Recent Developments5.14 Empire Genomics5.14.1 Empire Genomics Profile5.14.2 Empire Genomics Main Business5.14.3 Empire Genomics Products, Services and Solutions5.14.4 Empire Genomics Revenue (US$ Million) & (2015-2020)5.14.5 Empire Genomics Recent Developments5.15 Agilent5.15.1 Agilent Profile5.15.2 Agilent Main Business5.15.3 Agilent Products, Services and Solutions5.15.4 Agilent Revenue (US$ Million) & (2015-2020)5.15.5 Agilent Recent Developments5.16 Illumina5.16.1 Illumina Profile5.16.2 Illumina Main Business and Companys Total Revenue5.16.3 Illumina Products, Services and Solutions5.16.4 Illumina Revenue (US$ Million) (2015-2020)5.16.5 Illumina Recent Development and Reaction to Covid-19 6 North America6.1 North America Genomic Biomarker Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Genomic Biomarker Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Genomic Biomarker Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Genomic Biomarker Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Genomic Biomarker Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Genomic Biomarker Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more here:
New Report: Genomic Biomarker Market: Reporting and Evaluation of Recent Industry Developments| Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo...

Type 2 diabetes diet: Is it safe for diabetics to eat eggs for breakfast? Here is what you need to know  |  Photo Credit: iStock Images

New Delhi: Type 2 diabetes is a chronic condition that affects millions of people around the world. It is not just about the high levels of blood sugar, but also the collateral damage that diabetes can cause to the other vital organs. Diabetes can affect your heart, kidneys, and even liver. Following a healthy diet is extremely important for diabetes to keep their blood sugar levels managed, and avoid such complications.

Apart from following a low sugar diet, diabetics must also ensure they eat small, frequent meals, especially when they are taking diabetic medicine. Since breakfast is one of the most important meals of the day, here is what you need to know about type 2 diabetes and eating eggs for breakfast.

Eggs are considered an easy, tasty and healthy breakfast. However, what may be great for health for a normal person, may not be the best for diabetics as well. Eggs are a great source of protein, and very versatile to make. The good news is that eggs are also a great choice for people with diabetes. One large egg contains about only half gm carbs, and that is not enough to raise your blood sugar levels abnormally. According to the American Diabetes Association as well, diabetics must add eggs to their diet for blood sugar management.

Diabetics should add eggs to their diet and can eat them for breakfast. Diabetics should restrict their egg intake to three eggs per week, due to cholesterol concerns, since eggs are rich in cholesterol. They should also avoid the use of cheese, sauces, etc in the recipe for eggs. However, they can consume eggs as they wish poached, boiled, half-fried, etc. If you have existing cholesterol concerns, you must consume brown eggs instead of white.

Apart from eating a healthy diet, regular exercise is also very important to manage blood sugar levels and avoid complications. Yoga, running, or brisk walk are some exercises that can prevent and help in the management of type 2 diabetes.

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

More:
Type 2 diabetes diet: Is it safe for diabetics to eat eggs for breakfast? Here is what you need to know - Times Now

Living through a global pandemic, we can take some comfort from the enormous collaborative research and development response that is taking place to find a way out from under the shadow of the COVID-19 crisis. Scientists around the world are working to find new diagnostics, treatments and vaccines to use in the fight against the coronavirus.

Nathalie Moll is the Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The polar opposite of a pandemic, a rare disease may only affect a handful of patients in a particular country, but to the patient, their family, carers and clinicians, the impact of their condition can be just as devastating. Often genetic, discovered in childhood and frequently severe, rare diseases are some of the most significant scientific challenges in medicine. Typically they affect only 1 in 2,000 people, but there are more than 6000 rare diseases meaning around 30 million Europeans are living with some form of rare condition.

Rare diseases certainly dont attract the levels of media attention and interest that a public health crisis like COVID-19 does but for patients living with the 95% of rare diseases where no treatment options exist, the need for new diagnostics and medicines is every bit as real.

As the industry responsible for developing those new therapies, we are committed to achieving the crucial objective of finding new treatments for patients in areas of unmet medical need. It means supporting and strengthening the framework of incentives to drive further research into the next generation of treatments and cures for rare disease and paediatric treatments. Incentives drive investment, research and results. Results that mean new treatments and ultimately better outcomes for patients.

It is why EFPIA supports the existing European legislation on orphan medicines and paediatric medicines, while underlining the need to co-create vehicles to address issues around access to new treatments. Prior to the orphan legislation coming into force in 2000, there were just 8 treatments licensed for use to treat rare diseases, now there are 169, underlining the fundamental role that a predictable and stable incentives framework for research and development has. Any destabilisation of that framework threatens the investment in research and development in this area.

At the same time, faster, more equitable access to new rare disease treatments for patients across Europe is a shared goal and responsibility. Re-opening the Orphan Medicinal Product Regulation will not address the core challenges regarding unequal access and availability of orphan drugs within the EuropeanUnion. Addressing this challenge requires a structured dialogue with relevant stakeholders, Member States and the European Commission sensitive to their respective competence areas, to find solutions to introduce these ground-breaking treatments. That is why we reiterate the call to Member States and the Commission to set up a High-Level Forum composed of EU and national decision makers, patients, as well as the research and healthcare communities to find collaborative, multi-stakeholder solutions to these complex issues of access.

Considering the lack of innovation policy drivers in the Roadmap for the EUs Pharmaceutical Strategy, it is all the more critical that we maintain a stable and predictable incentives framework that can continue to support the development of new treatments for rare disease patients in Europe. We have to work together to ensure access to new treatments and technologies today, medical innovation in rare diseases for tomorrow and sustainable healthcare systems in a globally competitive Europe. Destabilising investment in the discovery and development of new treatments for patients living with rare diseases by re-opening a legislation, proven to be effective in stimulating the development of new treatments, cannot be the right approach.

One crystal clear lesson from the COVID-19 pandemic has been that the answer lies in medical innovation. This is equally true for patients living with rare diseases. Now is the time to re-build and re-invigorate rather than devalue Europes health research ecosystem, to make sure we address these challenges and #WeWontRest until we make treatments for rare diseases less rare.

View post:
From pandemic to rare disease, medical innovation is the answer - EURACTIV

Putting your employees and company culture first keeps the focus on inclusion and innovation, giving the company an incredible competitive advantage. At least thats the mantra at the heart of MyoKardia, a California-based biotech company that is developing precision medicine for cardiovascular diseases (CVDs).

We want to change the world for people with cardiovascular disease by taking a patient-focused, scientifically driven approach, Tassos Gianakakos, MyoKardias CEO, told BioSpace. When youre addressing hard problems, you need different opinions, approaches, and expertise at the table. That is the only way to effectively deliver on the mission.

Companies are at risk of getting it wrong when they dont focus on culture early on you need to launch out of the gate with a culture mindset, Gianakakos added. You get back what you put out there, so being a mission-driven, culture-valuing company will help draw in likeminded employees. That group genius is what enables remarkable improvements to health outcomes for society.

CVD, also called heart disease, is a blanket term used to describe many diseases that affect the heart or blood vessels. Globally, heart diseases are by far the number one killer in the world, with CVDs responsible for 17.9 million deaths worldwide. These conditions are highly prevalent throughout the population 30.3 million US adults have been diagnosed with CVDs.

Credit: WHO

We lose more people in the U.S. and around the world to cardiovascular conditions than any other disease, Gianakakos. MyoKardias entire purpose is to change that. We want to be the leading company developing precision medicine for CVDs. Our approach is different; were subtyping patient populations within these large, heterogeneous conditions so that we can identify effective, targeted therapeutics. The idea is to discover and develop medicines that have transformative potential for people.

MyoKardias late-stage pipeline focuses on two CVDs: hypertrophic cardiomyopathy (HCM), where the heart muscle becomes abnormally thick (hypertrophied), making it harder for the heart to pump blood; and dilated cardiomyopathy (DCM), where the hearts main pumping chamber (called the left ventricle) stretches and thins (dilates), making it harder for the heart to pump blood.

HCM is frequently caused by gene mutations in heart muscle proteins that cause the heart muscle to squeeze with more force than needed, leading to abnormal thickening over time. It is the most common inherited heart disease, occurring in about 1 in 500 people (over 650,000 people in the US). HCM is the most common cause of cardiac arrest (where the heart suddenly stops beating), in younger people. Although certain medications, like beta blockers and blood thinners, are used to treat some HCM symptoms, there arent any drugs that specifically address the underlying problem in HCM the genetic mutation-induced thickened heart muscle.

Positive results from a Phase III clinical trial of mavacamten, MyoKardias lead drug candidate for HCM, were announced in May. MyoKardia aims to submit a New Drug Application (NDA) submission with the FDA in the first quarter of 2021 and is planning for its first product launch.

DCMs causes may be varied in addition to genetics, a number of diseases are linked to left ventricle dilation, including diabetes, obesity, high blood pressure, infections, and drug and alcohol abuse. It is a common cause of systolic heart failure (where the heart isnt pumping blood as well as it should be). Medications such as angiotensin-converting enzyme (ACE) inhibitors, beta blockers, and blood thinners can successfully treat heart failure, but none of them are specific to the heart and have systemic side effects.

MyoKardias investigational drug danicamtiv is intended to increase heart contractions without interfering with the hearts ability to fill. The company recently reported encouraging data from their Phase IIa study of danicamtiv in chronic heart failure patients. They plan to advance into two new Phase II studies in specific patient populations: genetic DCM patients and systolic heart failure patients with paroxysmal or persistent atrial fibrillation (AFib).

BioSpace spoke to Gianakakos and Ingrid Boyes, MyoKardias Senior Vice President of Human Resources, about the companys pipeline, culture, and why building a culture of diversity and inclusion is foundational to a company.

(Boyes previously spoke to BioSpace in 2015 about what MyoKardia is looking for when theyre hiring.)

COMPANY CULTURE, DIVERSITY & INCLUSION

BioSpace: Why is company culture and diversity so important to a successful company? How do you promote diversity and inclusion at MyoKardia?

Gianakakos: The diseases we are tackling know no ethnic, gender or socioeconomic boundaries. So our company culture needs to reflect this. Our teams need to reflect this and the patients we are working to help. Its hard for us to see doing good science and achieving our mission any other way. And it goes beyond the science. To have a successful and meaningful company, we need to innovate more broadly in growth strategies, commercial models, and new ways to more effectively get our therapies to patients who need it around the world.

Im proud of how we embrace each others differences gender, ethnicity and race, orientation, socioeconomic status and beliefs -- and highlight the importance of company culture. Everyone at MyoKardia shares the same mission, the same values, but we embrace and value each persons differences. We want our employees to feel safe sharing their own voice and know that different points of view are valued and respected.

Boyes: Tassos passion for company culture is a large part of why I joined the company five years ago. As a Hispanic woman, its really important to me to create an environment where people can thrive and grow. We have fun while creating a valuable community. As employee number 50, I was able to focus on how to help build a company culture with Tassos that values diversity by building on employees experiences. We were very intentional about company culture and how we evolve it. Every voice at MyoKardia counts and every person plays an important role in improving CVD patients lives.

We actively seek input from our employees and encourage them to challenge the status quo. We also invite employees to lead activities and bring their unique perspectives to work.

Gianakakos: We want to bring great people who are passionate to the company and play to their strengths. Focusing on increasing their engagement and creating an energizing work environment allows employees to do their most creative and best work. Having people build the skills they want and need by cross-training and encouraging lifelong learning improves the connectivity and the innovation within the company.

We believe this is one of the key competitive advantages at MyoKardia connecting and supporting people to engage and excite them and ensuring they have a voice that is valued. Having diverse perspectives and a commitment to listening leads us to much better decisions and results.

What kind of diversity and engagement activities do you do both within MyoKardia and externally with the general public?

Boyes: We always strive to improve the culture by actively soliciting feedback from our employees though a number of channels, including engagement surveys. Implementing employee-led initiatives has brought great features into the companys culture, such as a womens forum that brings in external women speakers and identifies female role models, a green team focused on being more sustainable, and a community volunteer team that actively supports our community. All of these activities also help to develop valuable leadership skills regardless of title within our organization.

Gianakakos: Based on employee feedback, weve also implemented several policy changes, such as increasing the companys 401k match and giving each employee a six-week sabbatical once they have been with the company for six years.

Boyes: We want to be connected with diverse organizations and participate as much as possible externally connecting with others in the community with culture-focused passion. We are always looking to connect with driven people who share our company values.

Switching gears to the science, what does CVD drug development look like right now?

Gianakakos: In many ways, CVD is where oncology was 20 years ago there were no precision medicines and non-specific treatments such as chemotherapy and radiation were used regardless of cancer type. The number of drugs in development for CVDs is woefully low relative to its global burden. There are over 1,100 oncology drugs in development, but only 200 for cardiovascular diseases, despite CVDs killing more people annually than all cancers combined. In oncology today, precision medicine approaches have given us countless targeted therapies that have completely transformed patient care. We are making this happen today in CVD, where we feel may even have advantages over oncology given the many tools now available to monitor the heart, such as wearables and patches that measure the heart rate and rhythm.

What made you focus on precision cardiac medicine? Why now?

Gianakakos: Momentum around precision medicine in other disease areas was clearly growing and resulting in important advances when MyoKardia started eight years ago. The first cystic fibrosis drug that treated the underlying cause rather than the symptoms (ivacaftor) was just launched by Vertex and a few years prior to MyoKardia our founding investors were involved in launching several exciting new companies like Foundation Medicine, Agios and bluebird bio who were developing potentially game-changing targeted therapies.

Traditionally, CVD clinical trials are massive, expensive, and often fail. When there is a lack of understanding of the underlying disease biology and its unclear exactly what the drug is doing, that can result in a large signal-to-noise ratio. This in turn, requires larger studies which are more expensive, and the therapies have to benefit large numbers of patients for the investment to make sense. This is a recipe that doesnt lead to innovative or efficient drug discovery. Identifying smaller, more homogenous subgroups of patients who all share the same disease pathology, and targeting them with drugs designed specifically to address the underlying disease biology is so powerful. Were matching the tailored treatment to address each persons underlying condition understanding how to identify the right drugs for the right patients.

CARDIOVASCULAR DISEASE DRUG DEVELOPMENT & MYOKARDIAS PIPELINE

What are the major knowledge gaps that need to be addressed to make precision cardiac medicine achievable for many patients? What does the landscape look like right now for precision cardiac medicine?

Gianakakos: There needs to be a cultural shift in the CVD field to move away from grouping broad heterogenous patients together, to focusing on smaller, well defined patient groups treated with targeted therapies and learning as much as we can from those that respond very well and, as importantly, those that do not.

Matching patient profiles to drugs that specifically address their underlying disease is key. Leaning on existing technology, such as wearables, genetic sequencing, imaging, and biomarker profiles to subtype CVD patients and deeply understand the biological drivers of disease will lead to critically important targeted therapies and much more effective clinical trials.

In terms of other precision cardiac medicine approaches in development, gene therapies are being explored. While that technology is maturing, most gene therapies for CVDs are still in early-stage research, but eventually could be helpful for certain sub-groups of patients with CVD.

Relative to other disease areas, like oncology, it has been challenging for companies to invest in new approaches to drug discovery and development in areas like CVD and neurology. However, given the staggering medical need, and with progress being made by companies like ours, I expect interest in CVD precision medicine to increase over the next 3-5 years.

What does MyoKardias pipeline look like?

Gianakakos: Our Phase III drug, called mavacamten (MYK-461), is for HCM. HCM is a genetic disease where the heart thickens due to excessive force of contraction cause by mutations in the heart muscle proteins. There are two common subtypes of HCM: obstructive, where the thickening also occurs near the base of the aorta and prevents (obstructs) blood from flowing well out of the heart; and non-obstructive, where the thick muscle makes it challenging for the heart to relax and fill, reducing the amount of blood flow out of the heart without physically obstructing blood flow. About one-third of HCM patients have the non-obstructive type.

Mavacamten is a small molecule that targets the heart muscle protein myosin reducing the excessive force of contraction, directly addressing the underlying cause of HCM. We announced positive data from our Phase III trial (EXPLORER-HCM) of mavacemten in about 250 symptomatic obstructive HCM patients and we are now able to move full steam ahead on our first regulatory submission for approval. Encouraging results from a Phase II trial (MAVERICK-HCM) of mavacamten in about 60 participants with symptomatic non-obstructive HCM were recently presented and we are going to be moving mavacamten forward in non-obstructive patients. We are also conducting a long-term extension study is also ongoing for patients who participated in either EXPLORER-HCM or MAVERICK-HCM.

We started hyper focused in a disease with a defined genetic background and will expand in a deliberate way into adjacent diseases with similar problems, such as heart failure with preserved ejection fraction. About 3 million people in the U.S. have problems filling and relaxing their hearts and we estimate that approximately 10% of them share similar pathology to HCM. Are these disease subtypes related? Do they have similar genetic mutations? We plan to start a Phase II trial in the next few months to explore if mavacamten can help that specific heart failure population and learn much more about this devastating form of heart failure.

We also have a Phase II molecule, called danicamtiv (MYK-491), for DCM that is designed to increase the force of contraction in the heart - the opposite of what mavacamten has been created to do. Danicamtiv is a small molecule that selectively increases the number of myosin-actin cross bridges, supporting heart muscle contractions to help the heart pump more efficiently. It has recently completed a Phase Ib/IIa trial in DCM or stable heart failure patients and has shown very promising early results. We are now moving into a separate Phase II study in DCM patients with certain genetic mutations. Among the most interesting new findings from our clinical study of danicamtiv is that it appears to have a direct effect on the performance of the left atrium. We were able to confirm and learn more about these findings in nonclinical studies, which is leading us to explore danicamtiv in patients with systolic dysfunction and atrial fibrillation.

MyoKardia has gone from startup to successfully completing our first Phase III trial in eight years. In the coming months, we will be submitting our first drug to the FDA this year, which if approved will bring the first every therapy designed specifically for HCM to people with this debilitating condition.

We design our therapies with the aim of targeting the underlying disease mechanism to treat and, in some cases, reverse the problem, actually slowing down or reversing disease progression. That allows patients to live full lives, free from fear and complications. We are very excited and remain super ambitious. The magic and special sauce is really our employees and our culture.

Go here to see the original:
MyoKardia: The Precision Cardiac Medicine Company with Diversity and Inclusion at its Heart - BioSpace

A combined analysis of 10 prospective trials, intended to shed light on racial disparities in percutaneous coronary intervention (PCI) outcomes, saw sharply higher risks of death and myocardial infarction (MI) for Blacks compared with Whites.

The burden of comorbidities, including diabetes, was greater for Hispanics and Blacks compared to Whites, but only in Blacks were PCI outcomes significantly worse even after controlling for such conditions and other baseline risk factors.

The analysis based on more than 22,000 patients was published July 6 in JACC: Cardiovascular Interventions, with lead author Mordechai Golomb, MD, Cardiovascular Research Foundation, New York City.

In the study based on patient-level data from the different trials, the adjusted risk of MI after PCI was increased 45% at 1 year and 55% after 5 years for Blacks compared with Whites. Their risk of death at 1 year was doubled, and their risk of major adverse cardiac events (MACE) was up by 28% at 5 years.

"Improving healthcare and outcomes for minorities is essential, and we are hopeful that our work may help direct these efforts, senior author Gregg W. Stone, MD, Icahn School of Medicine at Mount Sinai, New York City, told theheart.org | Medscape Cardiology.

"But this won't happen without active, concerted efforts to promote change and opportunity, a task for government, regulators, payers, hospital administrators, physicians, and all healthcare providers," he said. "Understanding patient outcomes according to race and ethnicity is essential to optimize health for all patients," but "most prior studies in this regard have looked at population-based data."

In contrast, the current study used hospital source records, which are considered more accurate than administrative databases, and event coding reports, Stone said, plus angiographic core laboratory analyses for all patients, "allowing an independent assessment of the extent and type of coronary artery disease and procedural outcomes."

The analysis "demonstrated that even when upfront treatments are presumably similar [across racial groups] in a clinical trial setting, longitudinal outcomes still differ by race," Michael Nanna, MD, told theheart.org | Medscape Cardiology.

The "troubling" results "highlight the persistence of racial disparities in healthcare and the need to renew our focus on closing these gaps, [and] is yet another call to action for clinicians, researchers, and the healthcare system at large," said Nanna, of Duke University Medical Center, Durham, North Carolina, and lead author on an editorial accompanying the published analysis.

Of the 10 randomized controlled trials included in the study, which encompassed 22,638 patients, nine were stent comparisons and one compared antithrombotic regimens in patients with acute coronary syndromes (ACS), the authors note. The median follow-up was about 1100 days.

White patients made up 90.9% of the combined cohort, Black patients comprised 4.1%, Hispanics 2.1%, and Asians 1.8% figures that "confirm the well-known fact that minority groups are underrepresented in clinical trials," Stone said.

There were notable demographic and clinical differences at baseline between the four groups.

For example, Black patients tended to be younger than White, Hispanic, and Asian patients. Black and Hispanic patients were also less likely to be male compared with White patients.

Both Black and Hispanic patients had more comorbidities than Whites did at baseline, the authors observe. For example, Black and Hispanic patients had a greater body mass index compared with Whites, whereas it was lower for Asians; and they had more diabetes and more hypertension than Whites (P < .0001 for all differences).

Hispanics were more likely to have ACS at baseline compared with Whites and less likely to have stable coronary artery disease (CAD) (P < .0001 for all differences). Similar proportions of Blacks and of Whites had stable CAD, about 32% of each, and ACS, about 68% in both cases.

Rates of hyperlipidemia and stable CAD were greater and rates of ACS was lower in Asians than the other three race groups (P < .0001 for each difference).

In adjusted analysis, the risk of MACE at 5 years was significantly increased for Blacks compared with Whites (hazard ratio (HR),1.28; 95% CI, 1.05 - 1.57; P = .01). The same applied to MI (HR, 1.55; 95% CI, 1.15 - 2.09; P = .004).

At 1 year, Blacks showed higher risks for death (HR, 2.06; 95% CI, 1.26 - 3.36; P = .004) and for MI (HR, 1.45; 95% CI, 1.01 - 2.10; P = .045), compared with Whites.

No significant increases in risk for outcomes at 1 and 5 years were seen for Hispanics or Asians compared with Whites.

Covariates in the analyses included age, sex, body mass index, diabetes, current smoking, hypertension, hyperlipidemia, history of MI or coronary revascularization, clinical CAD presentation, category of stent, and race stratified by study.

Even with underlying genotypic differences between Blacks and Whites, much of the difference in risk for outcomes "should have been accounted for when the researchers adjusted for these clinical phenotypes," the editorial notes.

Some of the difference in risk must have derived from uncontrolled-for variables, and "Beyond genetics, it is clear that race is also a surrogate for other socioeconomic factors that influence both medical care and patient outcomes," they write.

The adjusted analysis, note Golomb et al, suggests "that for Hispanic patients, the excess risk for adverse clinical outcomes may have been attributable to a higher prevalence of risk factors. In contrast, the excess risk for adverse clinical outcomes for Black patients persisted even after adjustment for baseline risk factors."

As such, they agree, "The observed increased risk may be explained by differences that are not fully captured in traditional cardiovascular risk factor assessment, including socioeconomic differences and education, treatment compliance rates, and yet-to-be-elucidated genetic differences and/or other factors."

Stone said that such socioeconomic considerations may include reduced access to care and insurance coverage; lack of preventive care, disease awareness, and education; delayed presentation; and varying levels of provided care.

"Possible genetic or environmental-related differences in the development and progression of atherosclerosis and other disease processes" may also be involved.

"Achieving representative proportions of minorities in clinical trials is essential but has proved challenging," Stone said. "We must ensure that adequate numbers of hospitals and providers that are serving these patients participate in multicenter trials, and trust has to be developed so that minority populations have confidence to enroll in studies."

Stone reported holding equity options in Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestro Biomed, Aria, Cardiac Success, the MedFocus family of funds, and Valfix; and receiving consulting fees from Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore Ablative Solutions, Miracor, Neovasc, W-Wave, Abiomed, and others. Disclosures for the other authors are in the report. Nanna reports no relevant financial relationships; other coauthor disclosures are provided with the editorial.

JACC Cardiovasc Interv. 2020;13:1586-1595, 1596-1598. Abstract, Editorial

For more from TheHeart.org, follow us on Twitter and Facebook.

See the original post here:
Post-PCI Mortality Higher in Blacks vs Whites, Comorbidities Aside - Medscape

An emergency response team on 11 January at work in the Huanan Seafood Wholesale Market in Wuhan, China, initially said to be the source of COVID-19.

By Jon CohenJul. 10, 2020 , 4:30 PM

Science's COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.

The two-person team from the World Health Organization (WHO) traveling to China today to address the origin of the COVID-19 pandemic is unlikely to come home with answers. Rather, the duoan epidemiologist and an animal health expert whose names have not been releasedwill discuss with Chinese officials the scope of alarger international mission later, according to a WHO statement.

But this initial trip offers real hope that the mystery of the virus origins, which has become a political powder keg and the subject of countless conspiracy theories, will finally be investigated more thoroughly and transparently. (A similar WHO-led mission to examine how China was handling its fight against the virus, launched after weeks of diplomatic wrangling, returned in February with a surprising wealth of information.)

Science must stay open to all possibilities about the pandemics origins, Mike Ryan, executive director of WHOs Health Emergencies Programme, said at a press conference on 7 July. We need to lay out a series of investigations that will get the answers that Im sure the Chinese government, governments around the world, and ourselves really need in order to manage the risk going forward into the future.

Questions range from hunting for animals that might harbor the virus to examining the possibility that it came from a laboratory. There are plenty of details to investigate, and it could be a long road. Origin riddles for other new infectious diseases often took years to solve, and the route to answers has involved wrong turns, surprising twists, technological advances, lawsuits, allegations of cover ups, and high-level politics. Determining how a pathogen suddenly emerges in people requires a lot of sleuthing, but past successes offer clues of where to look for new insights, as do the few data points that now exist for SARS-CoV-2, the virus that causes COVID-19.

The initial, tidy origin story told by health officials in Wuhan during the first few weeks of January was that a cluster of people connected to a seafood market developed an unusual pneumonia, and that the outbreak stopped after the market was closed and disinfected. But confusion about the origin of the novel coronavirus identified in Wuhan patients arose when researchers published the first epidemiologic studies of the citys outbreak:Four of the first five casesconfirmed to have SARS-CoV-2 infections had no link to the market.

Soon, other theories emerged. Some believe its no coincidence that the city is host to the Wuhan Institute of Virology (WIV), home to leading bat coronavirus researcher Shi Zheng-Li. Her group, one of the first to isolate and sequence SARS-CoV-2, has trapped bats in the wild for 15 years, hunting for coronaviruses to help identify pandemic threats. In theirfirst report about the new virus, the scientists described a bat coronavirus in their collection that was 96.2% similar to SARS-CoV-2.

U.S. President Donald Trump early on endorsed speculation that the virus entered humans because of an accident at WIV. Amore contentious theoryis that the lab created the virus. (Researchers at the lab insist neither scenario has any merit, and evolutionary biologists elsewhere have argued the virus shows no evidence of having been engineered.)

The most popular hypothesis is that SARS-CoV-2 spread into humans from an intermediate host, an animal species susceptible to the virus that acted as a bridge between bats and humans. In the case of severe acute respiratory syndrome (SARS), civets turned out to play that role for the responsible coronavirus. For Middle East respiratory syndrome (MERS), also a coronavirus disease, itquickly became clearcamels were the culprit because highly similar viruses were found in the animals and people caring for them.

Chinese officials have reported conducting tests for SARS-CoV-2 at the Wuhan seafood market but what they foundremains sketchy. Chinas state-run news agency, Xinhua, said environmental samples tested positive for the virus in a zone of the market that sold wildlife, but the report had no details about the results or even a list of the species for sale. Other studies have discovered similarities between SARS-CoV-2 and a coronavirus found in pangolins, an endangered species that eats ants, but the pangolin virus is more divergent genetically from SARS-CoV-2 than the closest bat virus and theres no evidence pangolins or their scalesused in traditional Chinese medicinewere sold at the market.

Some more fringe theories still suggest SARS-CoV-2 came fromsnakes,cometary debris, or aU.S. Army lab.

So, assuming WHOs team and the Chinese government work out a deal for an international mission to study the pandemics origins, where would it start? Here are some key questions that need answers.

Scientists realized camels were the source of Middle East respiratory syndrome when highly similar viruses were found in the animals and people caring for them.

Another outstanding question is whether Shis team or other researchers in Wuhan manipulated bat viruses in gain-of-function experiments that can make a virus more transmissible between humans. In 2015, Shi co-authored a paper that made a chimeric SARS virus by combining one from bats with a strain that had been adapted to mice. Butthat workwas done at the University of North Carolina, not in Wuhan, and in collaboration with Ralph Baric. Did Shis group later carry out other gain-of-function studies in Wuhanand if so, what did they find?

Finally, diplomatic cablesfrom the U.S. Embassy in Beijing in 2018 warned that a new, ultra-high security lab at WIV had a serious shortage of appropriately trained technicians and investigators. Did Shis team ever work with coronaviruses in that lab, and, if so, why?

If history repeats itself, it might take yearsor even decadesto crack this case. Scientists havent unequivocally identified Ebolas source 45 years after its discovery. But the key, time and again, to clarifying the origins of emerging infectious diseases is unearthing new data. WHOs push to organize the probe promises to, at the very least, accelerate what has been a plodding pursuit for answers.

Continue reading here:
A WHO-led mission may investigate the pandemic's origin. Here are the key questions to ask - Science Magazine

Over the past 20 years the Segway has become ubiquitous on city streets and industrial campuses, in malls and even on wooded trails. The electrically charged, stand-and-ride personal transporter, an oft-parodied icon of the Silicon Valley tech world, quickly gained popularity among law enforcement and security agencies, as well as recreational tour operators around the world.

But the time for the original self-balancing standing scooter has come to a close. According to All Things Considered, Ninebot, the company that now owns Segway, will retire the device on July 15. But its creator, Dean Kamen, has bold new plans.

Kamen made a name for himself as an inventor of medical devices, including the insulin pump. Initially, the Segway grew out of his work on a self-balancing wheelchair. When the Segway launched in December 2001, Kamen believed the new device would transform cities, replacing cars and their pollution with residents gliding down green streets, each one on a segway, writes Liz Brody for OneZero. He told Time magazine it would be to the car what the car was to the horse and buggy.

Despite their widespread use, Segways never became the mobility machines of the future that Kamen dreamed, and in fact, have been criticized for being the cause of countless accidental injuries and deaths. But these incidents did not deter Kamen who, Brody writes, is still busy inventing. Kamen currently holds more than 440 patents in the United States and internationally. And, if successful, his next bright idea, unlike the Segway, might actually have a positive impact on human health: Kamen is now in the market to mass-produce human organs.

More than 110,000 people in the U.S. alone are in need of an organ transplant, and each day 20 people die waiting for a replacement organ. Those who do receive transplants can be at high risk of their body rejecting the organ. For those suffering from failing organs, some hope sprang in the 1990s when scientists began engineering human tissues.

Significant progress has been made in the field since the 90s, and just last year researchers from Tel Aviv University announced they were the first to bioprint a human heart, reports FreeThinks Kristen Houser. Using methods similar to those employed when 3-D printing solid objects from digital models, bioprinting uses living cells to create computer-generated tissue grafts.

Mass availability of lab-grown organs may seem far off to some, but Kamen is poised to spearhead production when the time comes. In 2016, Kamen teamed up with Martine Rothblatt, the head of biotech company United Therapeutics, who was, at the time, working on growing artificial lungs. According to OneZero, the two had already begun collaborating when they heard about a U.S. Department of Defense (DOD) grant opportunity for a scalable process of manufacturing human organs. Kamen and his collaborators won the $80 million DOD grant to manufacture replacement tissue and organs on-demand.

"We need to essentially make the printing press for the world of regenerative medicine, said Kamen at the time.

The grant kickstarted the formation of Advanced Regenerative Manufacturing Institute (ARMI), a nonprofit consortium of around 170 companies, institutions and organizations from across the country, which works hand-in-hand with Kamens BioFabUSA. With a staff and board of directors boasting FDA, Microsoft and Boston Scientific alumni, the group has continued to contribute and raise additional funds, and set up shop in a New Hampshire millyard.

This collaboration is what could enable Kamen to have the world-transformative impact hes hoped for. While other endeavors in the field have been siloedwith policy, robotics, organ and stem-cell research, and biotech engineering all operating more or less independentlynone have yet achieved the printing press factory model that Kamen described.

When youre in this industry and youre thinking about scale, you cant go to Home Depot, Michael Lehmicke, director of science and industry affairs at the Alliance for Regenerative Medicine, told OneZero. Whats unique about ARMI, is theyre thinking of how you would actually scale the system when it is fully commercialized.

Of course, while some have been critical, or at the very least skeptical of Kamens work in the past, Gizmodos Joanna Nelius, for one, is intrigued by the latest prospect.

I had knee surgery to replace my torn ACL over 10 years ago, but the cadaver tendon used to replace it disintegrated inside my joint, so Ive been living without that connective tissue for a decade, she writes. All thats left are two screws that once held it in place, one burrowed into my tibia and the other in my femur. If Kamens vision comes true, then perhaps in the future Ill have my own printed tissue put in its place.

Continue reading here:
As Segway Retires, Its Inventor Gears Up to Grow Organs - Smithsonian Magazine

AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today preliminary unaudited results for the fourth quarter and full year ended June 30, 2020, together with a company update.

Preliminary Unaudited Results for Three Month Period Ended June 30, 2020

With effect from July 1, 2020, the Company is reporting financial results in United States dollars (US$), and prepared in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP).

To compare with the Companys previously reported results (as reported under IFRS) fourth quarter net revenue was approximately A$6.08M, versus A$5.96M in the third quarter, or an increase of 2.0%.

"We are pleased with our fourth quarter results given the challenges and limited patient and facility access that we have experienced with the onset of the COVID-19 pandemic," said Dr. Mike Perry, AVITA Therapeutics Chief Executive Officer. "Like many others, this quarter we witnessed the most challenging commercial conditions since the RECELL System was launched in the U.S. in early 2019. While burns are not considered elective procedures, the incidence of burns was not immune to the impact of COVID-19 as nationwide protective (executive) orders drove a reduction in accidents resulting in burn injuries. Despite the tough macro environment, the clear benefits of the RECELL System including shortened length of hospital stays, together with less invasive and fewer surgeries, continues to resonate with hospitals, physicians, and patients, which is reflected in our results this quarter."

Preliminary Unaudited Results for the Full Year Ended June 30, 2020

To compare with the Companys previously reported results (as reported under IFRS) fiscal 2020 sales were approximately A$21.72M, an increase of A$14.02M or 182% over the A$7.71M recognized during the previous full year.

To compare with the Companys previously reported results (as reported under IFRS) fiscal 2020 sales were approximately A$21.03M, an increase of A$14.82M or 238% over the A$6.21M recognized during the previous full year.

Company Update

Quarter Ended June 30, 2020

During the fourth quarter we witnessed a wide degree of variability with both revenue and procedural volumes, together with an environment where our customers mandated highly restrictive access practices for our field force given the COVID-19 pandemic. Face-to-face interaction with our burn caregivers continues to be exclusively at "physician request" for case support within the operating theater only, and does not permit participation in the aftercare setting or otherwise enable clinical and business development, for example, to expand utilization of the RECELL System across different burns and users. Given the current state of affairs, we have no reason to believe that these measures, and our limited access, will change in the short term.

As previously stated, burn procedures are neither elective nor deferrable, however the rate of occurrence of these events is very dependent on broader economic activity and "people movement". As such, we saw many of our customers initially experience reduced burn volumes due to the social distancing and shelter-in-place restrictions that have been implemented across the nation.

The reprioritization of hospital resources to support COVID-19 readiness meant that our April results were the lowest monthly revenue and procedural volumes seen this calendar year. Fortunately, as the quarter developed, the benefits of the RECELL System providing reduced hospital stays, and fewer and smaller surgeries, together with both a gradual uptick in burn incidence and hospitals (partially) reverting back from a COVID-19 centric focus, enabled a recovery of both revenue and procedural volume growth through May and June. As with many companies in the current pandemic environment, it is difficult to predict revenue and procedural volume over the coming months, but we are pleased with current utilization rates and our physician commitment.

BARDA

The Company continues to work with the U.S. Biomedical Advanced Research and Development Authority (BARDA) on the procurement of the RECELL System for the U.S. strategic national stockpile for public health medical emergencies (with an estimated contract value of US$7.6 million). The Company is hopeful of providing further updates on this topic during this quarter.

Future Market Opportunities

Set out below is an update on our various future market opportunities:

On July 1, 2020, the FDA approved the IDE application for the pivotal study which is titled "A Prospective Multi-Arm Blinded-Evaluator Within-Subject Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo."

The Company is continuing to work with FDA to finalize two (2) outstanding study design considerations and will provide further updates, including details regarding the study and initiation plan, over the next several weeks.

The Company expects to commence enrollment in the vitiligo pivotal study in the second half of this calendar year.

The Company continues to have a high degree of confidence that the RECELL System can be an effective therapeutic offering for patients with stable vitiligo. More than 1,000 patients have been treated with the RECELL System for vitiligo outside of the United States, and to date there are eight (8) publications demonstrating the benefits of the RECELL System in vitiligo.

By comparison, since October 1, 2019 the Company has benefited from various reimbursement codes for patients admitted for burn treatment in the inpatient hospital setting (under the Hospital Inpatient Prospective Payment System (IPPS)), including the following:

Medicare reimburses hospitals for inpatient services using MS-DRGs (Medicare Severity Diagnosis-Related Groups) (see MS-DRG 927, 928 and 929 for various types of burns (which are non-specific to the RECELL System)).

Specific ICD-10-PCS code series describing our "cell suspension technique" for the use of the RECELL System (see the "OHR" codes within ICD-10-PCS). These procedure codes are assigned to the same DRGs for payment as other skin grafts.

Current Procedural Terminology (CPT) for physicians to support reimbursement for physician rendered healthcare services.

There is no procedure-specific CPT code for the RECELL Systems cell suspension autografting and so, per recommendations from the American Burn Association, providers using the RECELL System are guided to the existing long-standing epidermal autografting codes (e.g. CPT code 151101 and 15115)2.

In the outpatient setting, the Company has been seeking a New Technology Ambulatory Payment Classification (APC) under the Outpatient Prospective Payment System (OPPS) since late 2019. However, based on feedback from The Centers for Medicare & Medicaid Services (CMS) and given recent changes to the OPPS payments system discussed below, the Company will now instead pursue a Transitional Pass-through Payment Application (TPT) to support separate additional Medicare payment for the RECELL System.

CMS has advised the Company that the availability of the long-standing CPT code 15110 and CPT code 15115 (which providers may presently utilize in both the inpatient and outpatient hospital setting) excludes our ability to apply for a New Technology APC for use in the outpatient setting.

On January 1, 2020, CMS implemented changes to the OPPS and ambulatory surgical centers (ASC) payment systems to permit medical devices, including the RECELL System, "that have received FDA marketing authorization and are part of the Breakthrough Devices Program [to] be approved [by CMS for TPT] through the quarterly [review] process" (as opposed to the typical annual review process).

TPT was established by CMS to provide an alternative payment pathway for "transformative medical devices". Similar to the New Technology APC, if approved CMS would create a new C code and would allow the RECELL System to be billed and paid separately in hospital outpatient facilities and ASCs.

As a recipient of Breakthrough Device status, AVITA Therapeutics will work with CMS through the next CMS scheduled quarterly review cycle and is hopeful of having a C code in place for the RECELL System on January 1, 2021 (which should not change our current commercialization timeline for the outpatient hospital setting).

Enrollment of clinical studies across the United States are largely paused at present and the Companys enrollment of the aforementioned studies are accordingly largely on hold.

The Company has enrolled three (3) patients in the pediatric scald study and one (1) patient in the soft tissue reconstruction study.

The Company anticipates that enrollment will resume in the ensuing quarter.

Publications

Notable publications released during the quarter were as follows:

Japan

AVITA Therapeutics continues to work with our Japanese marketing partner, COSMOTEC, to advance our application for approval to market the RECELL System in Japan pursuant to Japans Pharmaceuticals and Medical Devices Act. The application has been constructed broadly to seek approval for the treatment of patients with burns, chronic wounds and vitiligo in three (3) size configurations of the RECELL System.

Story continues

Progress on the application has been delayed due to the COVID-19 pandemic and the associated State of Emergency declaration in Japan. In addition, Japans regulatory agency, the Pharmaceuticals and Medical Devices Agency (PMDA), has now requested various non-clinical "raw data" (e.g., original hand written copies of data entry forms or records) of a small subset of our historic studies, some of which were conducted more than ten (10) years ago. To facilitate PDMAs request, AVITA Therapeutics is repeating three (3) non-clinical or "benchtop" tests. These tests are expected to be completed and submitted in August, and the Company hopes to then advance our application for approval of the RECELL System in Japan.

Other Updates

Authorized for release by the Chief Executive Officer of Avita Therapeutics, Inc.

ABOUT AVITA THERAPEUTICS, INC.

AVITA Therapeutics is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Therapeutics patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Therapeutics first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "intend," "could," "may," "will," "believe," "estimate," "look forward," "forecast," "goal," "target," "project," "continue," "outlook," "guidance," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

1 CPT code 15110: Epidermal autograft, trunks, arms, legs; CPT code 15115: Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and / or multiple digits.2 It should be noted that the CPT code may be used in both the inpatient and the outpatient hospital setting.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005311/en/

Contacts

FOR FURTHER INFORMATION:

U.S. Media Sam Brown, Inc. Christy CurranPhone +1 615 414 8668christycurran@sambrown.com

O.U.S Media Monsoon Communications Rudi MichelsonPhone +61 (0)3 9620 3333Mobile +61 (0)411 402 737rudim@monsoon.com.au

Investors: Westwicke Partners Caroline CornerPhone +1 415 202 5678caroline.corner@westwicke.com

AVITA Therapeutics, Inc. David McIntyreChief Financial OfficerPhone +1 661 367 9178dmcintyre@avitamedical.com

Go here to see the original:
AVITA Therapeutics Provides Company Update and Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2020 - Yahoo Finance

Mystified by the need for defibrillation to save a 10-year-old from drowning, Michael Ackerman, M.D., Ph.D., vowed to dig for answers. That pivotal case during a Mayo Clinic pediatric cardiology residency was the catalyst for Dr. Ackermans career in genetic sleuthing of inherited sudden cardiac death syndromes. With help from the Center for Regenerative Medicine Biotrust, Dr. Ackermans team reprograms cell lines to zero in on precise causes and possible treatments for genetic heart disorders that increase the risk of sudden cardiac death. His research and practice focuses on inherited conditions like long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT) and Brugada syndrome (BrS) along with heart muscle diseases such as hypertrophic cardiomyopathy (HCM).

Working with the Center for Regenerative Medicine has opened up a whole new investigative arm to our lab. It is bench to bedside research. We take cells from a blood sample my patients and then reprogram those cells to become cardiac cells. This research effort has been a powerful tool in gene discovery to prove beyond a shadow of a doubt when a monogenetic variant is indeed the cause of a sudden cardiac death syndrome, says Dr. Ackerman.

Reprogramming cells to identify disease-causing mutations

Reprogramming a patients cells is like a step back in time to when the cells were initially forming in the mothers womb. At that time, cells were dividing and could become any type of cell or tissue in the body. Reprogrammed cells, known as induced pluripotent stem cells, can be redirected to become new heart cells. Dr. Ackermans team uses these patient-specific cell lines to create a disease in a dish model and investigate whether genetic mutations are causing the patients genetic heart disease such as long QT syndrome.

Once we think weve found the root cause of disease, we then go to the patients cell line. We ask, does it show in the dish, in that patients re-engineered heart cells, a prolonged QT cellular phenotype? If it does, then we edit out and correct that variant of interest and at the cellular level test whether the abnormality disappears, says Dr. Ackerman.

Dr. Ackermans team then introduces that genetic variant into normal, healthy cells. If those cells produce a long QT phenotype, they have proof that exact genetic variant is the cause.

Using this disease in a dish model and other genetic sleuthing strategies, Dr. Ackermans team has discovered six of the 17 known genes that cause long QT syndrome. And, they have recently described two entirely new syndromes. One is triadin knockout syndrome, a heart arrhythmia that could lead to cardiac arrest in children during exercise. The second is an autosomal recessive genetic mechanism for calcium release channel deficiency syndrome, prevalent within Amish communities. That key discovery solved the mystery of why so many Amish children were dying suddenly during ordinary childhood play. The disease in a dish model is also useful for discovering new therapies. After creating the patients disease in a dish, Dr. Ackermans team tests potential new drug compounds to see if they could be effective.

We are developing a new gene therapy for the most common genetic subtype of long QT syndrome.With this model, the gene therapy vector is essentially curing the diseased long QT phenotype in the dish, says Dr. Ackerman.

Almost quit research

Dr. Ackerman began medical and graduate school at Mayo Clinic in 1988, where he worked in a research lab next to then fellow trainee, Andre Terzic, M.D., Ph.D., who now is director of Mayo Clinic Center for Regenerative Medicine. Initially not seeing the relevance to patient care, Dr. Ackerman finished his Ph.D. and left research vowing to never, ever return. True to his mentors predictions that youll be back, Mike, Dr. Ackerman felt the pull back to research to address unmet medical needs of his patients.He joined Mayo Clinics faculty in 2000 as one of the first genetic cardiologists with a goal of establishing a practice for patients at risk of sudden cardiac death from genetic heart diseases. Dr. Ackerman now directs the Mayo Clinic Windland Smith Rice Genetic Heart Rhythm Clinic and the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory.

Dr. Ackermans return to research has provided many answers for patients, with over 600 peer-reviewed publications that have occurred since that time 23 years ago when Dr. Ackerman and his team first solved that 10-year-old boys near fatal drowning. It was a mutation in the gene causing type 1 long QT syndrome.

Dr. Ackerman is one of the innovators the Center for Regenerative Medicine collaborates with as it seeks to be a global leader and trusted destination for regenerative care driven by research and education.

###

Tags: Brugada syndrome, Center for Regenerative Medicine Biotrust, hypertrophic cardiomyopathy, long Q T syndrome, Mayo Clinic Center for Regenerative Medicine, Michael Ackerman, People, Research, Stem cell research, sudden cardiac death

See original here:
Using stem cells to find causes and treatments to prevent ...

Request free mailed brochure

IntroductionThe Architecture of the NeuronBirthMigrationDifferentiationDeathHope Through Research

Until recently, most neuroscientists thought we were born with all the neurons we were ever going to have. As children we might produce some new neurons to help build the pathways - called neural circuits - that act as information highways between different areas of the brain. But scientists believed that once a neural circuit was in place, adding any new neurons would disrupt the flow of information and disable the brains communication system.

In 1962, scientist Joseph Altman challenged this belief when he saw evidence of neurogenesis (the birth of neurons) in a region of the adult rat brain called the hippocampus. He later reported that newborn neurons migrated from their birthplace in the hippocampus to other parts of the brain. In 1979, another scientist, Michael Kaplan, confirmed Altmans findings in the rat brain, and in 1983 he found neural precursor cells in the forebrain of an adult monkey.

These discoveries about neurogenesis in the adult brain were surprising to other researchers who didnt think they could be true in humans. But in the early 1980s, a scientist trying to understand how birds learn to sing suggested that neuroscientists look again at neurogenesis in the adult brain and begin to see how it might make sense. In a series of experiments, Fernando Nottebohm and his research team showed that the numbers of neurons in the forebrains of male canaries dramatically increased during the mating season. This was the same time in which the birds had to learn new songs to attract females.

Why did these bird brains add neurons at such a critical time in learning? Nottebohm believed it was because fresh neurons helped store new song patterns within the neural circuits of the forebrain, the area of the brain that controls complex behaviors. These new neurons made learning possible. If birds made new neurons to help them remember and learn, Nottebohm thought the brains of mammals might too.

Other scientists believed these findings could not apply to mammals, but Elizabeth Gould later found evidence of newborn neurons in a distinct area of the brain in monkeys, and Fred Gage and Peter Eriksson showed that the adult human brain produced new neurons in a similar area.

For some neuroscientists, neurogenesis in the adult brain is still an unproven theory. But others think the evidence offers intriguing possibilities about the role of adult-generated neurons in learning and memory.

The central nervous system (which includes the brain and spinal cord) is made up of two basic types of cells: neurons (1) and glia (4) & (6). Glia outnumber neurons in some parts of the brain, but neurons are the key players in the brain.

Neurons are information messengers. They use electrical impulses and chemical signals to transmit information between different areas of the brain, and between the brain and the rest of the nervous system. Everything we think and feel and do would be impossible without the work of neurons and their support cells, the glial cells called astrocytes (4) and oligodendrocytes (6).

Neurons have three basic parts: a cell body and two extensions called an axon (5) and a dendrite (3). Within the cell body is a nucleus (2), which controls the cells activities and contains the cells genetic material. The axon looks like a long tail and transmits messages from the cell. Dendrites look like the branches of a tree and receive messages for the cell. Neurons communicate with each other by sending chemicals, called neurotransmitters, across a tiny space, called a synapse, between the axons and dendrites of adjacent neurons.

There are three classes of neurons:

Scientists think that neurons are the most diverse kind of cell in the body. Within these three classes of neurons are hundreds of different types, each with specific message-carrying abilities.

How these neurons communicate with each other by making connections is what makes each of us unique in how we think, and feel, and act.

The extent to which new neurons are generated in the brain is a controversial subject among neuroscientists. Although the majority of neurons are already present in our brains by the time we are born, there is evidence to support that neurogenesis (the scientific word for the birth of neurons) is a lifelong process.

Neurons are born in areas of the brain that are rich in concentrations of neural precursor cells (also called neural stem cells). These cells have the potential to generate most, if not all, of the different types of neurons and glia found in the brain.

Neuroscientists have observed how neural precursor cells behave in the laboratory. Although this may not be exactly how these cells behave when they are in the brain, it gives us information about how they could be behaving when they are in the brains environment.

The science of stem cells is still very new, and could change with additional discoveries, but researchers have learned enough to be able to describe how neural stem cells generate the other cells of the brain. They call it a stem cells lineage and it is similar in principle to a family tree.

Neural stem cells increase by dividing in two and producing either two new stem cells, or two early progenitor cells, or one of each.

When a stem cell divides to produce another stem cell, it is said to self-renew. This new cell has the potential to make more stem cells.

When a stem cell divides to produce an early progenitor cell, it is said to differentiate. Differentiation means that the new cell is more specialized in form and function. An early progenitor cell does not have the potential of a stem cell to make many different types of cells. It can only make cells in its particular lineage.

Early progenitor cells can self-renew or go in either of two ways. One type will give rise to astrocytes. The other type will ultimately produce neurons or oligodendrocytes.

Once a neuron is born it has to travel to the place in the brain where it will do its work.

How does a neuron know where to go? What helps it get there?

Scientists have seen that neurons use at least two different methods to travel:

Not all neurons are successful in their journey. Scientists think that only a third reach their destination. Some cells die during the process of neuronal development.

Some neurons survive the trip, but end up where they shouldnt be. Mutations in the genes that control migration create areas of misplaced or oddly formed neurons that can cause disorders such as childhood epilepsy. Some researchers suspect that schizophrenia and the learning disorder dyslexia are partly the result of misguided neurons.

Once a neuron reaches its destination, it has to settle in to work. This final step of differentiation is the least well-understood part of neurogenesis.

Neurons are responsible for the transport and uptake of neurotransmitters - chemicals that relay information between brain cells.

Depending on its location, a neuron can perform the job of a sensory neuron, a motor neuron, or an interneuron, sending and receiving specific neurotransmitters.

In the developing brain, a neuron depends on molecular signals from other cells, such as astrocytes, to determine its shape and location, the kind of transmitter it produces, and to which other neurons it will connect. These freshly born cells establish neural circuits - or information pathways connecting neuron to neuron - that will be in place throughout adulthood.

But in the adult brain, neural circuits are already developed and neurons must find a way to fit in. As a new neuron settles in, it starts to look like surrounding cells. It develops an axon and dendrites and begins to communicate with its neighbors.

Although neurons are the longest living cells in the body, large numbers of them die during migration and differentiation.

The lives of some neurons can take abnormal turns. Some diseases of the brain are the result of the unnatural deaths of neurons.

- InParkinsons disease, neurons that produce the neurotransmitter dopamine die off in the basal ganglia, an area of the brain that controls body movements. This causes difficulty initiating movement.

- InHuntingtons disease, a genetic mutation causes over-production of a neurotransmitter called glutamate, which kills neurons in the basal ganglia. As a result, people twist and writhe uncontrollably.

- InAlzheimers disease, unusual proteins build up in and around neurons in the neocortex and hippocampus, parts of the brain that control memory. When these neurons die, people lose their capacity to remember and their ability to do everyday tasks. Physical damage to the brain and other parts of the central nervous system can also kill or disable neurons.

-Blows to the brain, or the damage caused by a stroke, can kill neurons outright or slowly starve them of the oxygen and nutrients they need to survive.

-Spinal cord injurycan disrupt communication between the brain and muscles when neurons lose their connection to axons located below the site of injury. These neurons may still live, but they lose their ability to communicate.

Scientists hope that by understanding more about the life and death of neurons they can develop new treatments, and possibly even cures, for brain diseases and disorders that affect the lives of millions of Americans.

The most current research suggests that neural stem cells can generate many, if not all, of the different types of neurons found in the brain and the nervous system. Learning how to manipulate these stem cells in the laboratory into specific types of neurons could produce a fresh supply of brain cells to replace those that have died or been damaged.

Therapies could also be created to take advantage of growth factors and other signaling mechanisms inside the brain that tell precursor cells to make new neurons. This would make it possible to repair, reshape, and renew the brain from within.

For information on other neurological disorders or research programs funded by the National Institute of Neurological Disorders and Stroke, contact the Institute's Brain Resources and Information Network (BRAIN) at:

BRAINP.O. Box 5801Bethesda, MD 20824(800) 352-9424www.ninds.nih.gov

Top

Prepared by:Office of Communications and Public LiaisonNational Institute of Neurological Disorders and StrokeNational Institutes of HealthBethesda, MD 20892

NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.

All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.

View post:
Brain Basics: The Life and Death of a Neuron | National ...

TORONTO, July 08, 2020 (GLOBE NEWSWIRE) -- CB2 Insights Inc. (CB2 or the Company) (CSE: CBII; OTCQB: CBIIF), will be hosting its Q1 2020 earnings call on Wednesday, July 15, 2020 at 9:00 a.m. Eastern Daylight Time (EDT).

CB2 will issue a press release and file its interim financial statements and interim Quarterly Management Discussion and Analysis (MD&A) for the quarter ended March 31, 2020 (the Q1 2020 Filings) after the close of markets on July 14, 2020.

Conference call details:

A replay of the earnings call will be available on the companys website 24 hours after the call takes place.

Submitting Questions:

Those interested in submitting questions for the earnings call can do so by emailing investors@cb2inisghts.com prior to the start of the call. CB2 Insights will attempt to answer all questions submitted, however some questions may not be answered during the call due to time constraints.

The Company looks forward to providing additional discussion on its Q1 2020 Filings, as well as providing an update on the business and preliminary expectations for Q2 2020. Further, the Company will update shareholders on its future outlook and plans for growth in the coming quarters.

About CB2 Insights

CB2 Insights (CSE:CBII OCT:CBIIF) CB2 Insights is a healthcare services and technology company, working to positively impact patient health outcomes. Our mission to mainstream alternative health treatments into traditional healthcare by recognizing the need for patient treatment diversity, and the impacts of integrating alternative and conventional medicine. The Company works primarily to roster and treat patients who are seeking alternative treatments due to the ineffectiveness of conventional medicine, and the inability to find support through their existing care network, or in some cases, inability to access a primary care network. Medical services offered by the Company are defined as Integrative medicine, where we work to understand the real world evidence for the safety, impact and effectiveness of medical treatments including plant based medicines that often lack sufficient research and therefore adoption by conventional healthcare providers.

To support patient care and positive health outcomes, the Company is also focused on advancing safety and efficacy research surrounding alternative health treatments by monitoring and assessing Real-World Data (RWD) and providing Real-World Evidence (RWE) through our proprietary technology, data analytics, and a full service contract research organization.

The Companys primary operations are in the United States, with application to its insights, technology and research services deployed in other International markets including Canada, United Kingdom and Colombia.

The Companys disciplined operating model, allows patients to receive access to care in a time efficient and cost-effective manner. Utilizing virtual telehealth and over 30 physical brick and mortar clinics, the Company currently treats over 100,000 patients across 12 States. Utilizing proprietary technology and data analytic platforms, the Company is able to monitor, study and assess a variety of healthcare treatments and products for the safety, efficacy and effectiveness. The Company believes it is well positioned to be the research and technology partner of choice for multiple stakeholders including Big Pharma, Life Sciences, Regulatory Bodies and Payors within the traditional and integrative medical industry.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2s filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the Companys unaudited financial results and projected growth.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Read more:
CB2 Insights to Host Q1 2020 Earnings Call on July 15, 2020 - GlobeNewswire

Get to know Internist Dr. Umbrine Fatima, who serves patients in Clarence, New York.

(YorkPedia Editorial):- New York City, Jul 10, 2020 (Issuewire.com)Recognized as a reputable, board-certified internist, Dr. Fatima strives to help patients live their best and achieve their individual health and wellness goals. She is the owner & operator of My Health 360, a membership-based premier concierge internal medicine practice which also offers medical esthetic procedures in Clarence, New York.

Patients suffering from diabetes, high cholesterol, high blood pressure, arthritis, hormone imbalance, chronic pain, obesity, or other chronic conditions can turn to My Health 360 for premium care. A firm believer in taking a holistic approach to care, Dr. Fatima focuses on each patient as an individual instead of just treating their medical condition(s). She uses personalized, alternative, and lifestyle strategies were needed to enhance ones quality of life.

From health to wellness, the doctor and her team of skilled professionals offer the following services: aesthetics, concierge care, cosmeceuticals, deprescribing, genomic testing, hair products and treatments, iCARI Data Wallet, pain management, and weight management.

Aesthetics: Helping patients to look and feel rejuvenated using simple, minimally invasive solutions, Dr. Fatima and her expert esthetic team offer botox, fillers, herbal facial serums, hair loss treatments, and nonsurgical face-lifts. They strive to help each patient achieve desired effects, including tighter, lifted skin; younger looking skin; better facial symmetry; restored facial volume; and fewer skin creases and folds.

Concierge care: My Health 360 Concierge Care offers an old-fashioned direct patient-physician relationship with premium medical care at an affordable membership fee of $1,500 per person per year, which entitles members up to four medical visits per year, including some lab tests. House visits, if deemed medically necessary, may be available for an additional cost.

Cosmeceuticals: Cosmeceuticals are cosmetic products and treatments with therapeutic properties that improve the look and health of ones skin well after their application. With a holistic and integrative approach to care, Dr. Fatima combines traditional medical treatments with alternative therapies to improve overall health and wellness. Utilizing cosmeceuticals, the goal is to help each patient meet their esthetic goals, while also caring for the underlying cause of their individual beauty concerns.

Deprescribing: Dr. Fatima and her colleagues offer deprescribing strategies to optimize medication regimens or reduce the number of medications patients take in favor of healthy lifestyle changes. They will review a patients symptoms, medical history, medication list, and advise on possible interactions and adverse effects one may be experiencing with recommendations to deprescribe if needed. The goal of deprescribing is to maintain or improve quality of life.

Genomic testing: From a simple cheek swab, Dr. Fatima and her experienced team access copious amounts of genomic data (DNA makeup, biochemistry, metabolism, and more) and analyze broad or specific areas of concern. They deliver personalized, actionable information, providing patients with evidence-based roadmaps for effective dietary and lifestyle interventions based on their unique genetic and biochemical needs.

Pain management: Chronic pain management at My Health 360 involves treatments that ease long-lasting pain without addictive opioids or invasive surgery. Dr. Fatima reviews each patients symptoms and medical history completes an exam and may use blood or imaging tests to diagnose the cause of their pain and develop personalized chronic pain treatments with a goal to restore quality of life naturally.

Weight management: Weight management at My Health 360 is a medically supervised program with proven success that helps patients achieve or maintain a desirable weight and lower their risk of chronic diseases. Alongside her team, Dr. Fatima uses sophisticated methods, including genomics-guided lifestyle modifications, to guide treatment decisions which may be based on hormone levels, food cravings, nutrient utilization, metabolism, thyroid function, biochemistry, and other genetic factors. By doing so, she develops personalized diets and exercises plans to get patients on track with a healthy lifestyle.

With over two decades of experience in her field, Dr. Fatima earned her medical degree from DOW University of Health Sciences in Pakistan. Upon relocating to the United States, she completed her residency in internal medicine at NewYork-Presbyterian Queens.

Following her education, she became board-certified in internal medicine by the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

A physician informaticist with an extensive background in health informatics and data analytics consulting, Dr. Fatima is the President and Founder of Health Information Technology Consultants, Inc. She combines her clinical and informatics experience to help healthcare organizations implement technologies that balance best security practices and efficient clinical workflows with a focus on patient safety while minimizing physician burnout. To date, she has successfully led many health information technology projects to support business needs of healthcare organizations throughout North America.

Licensed to practice medicine in New York and Florida, Dr. Fatima is also the Medical Director of Capacity for Development of Mentally Disabled Adults through SASINC.org. She is a Fellow of the American College of Physicians (FACP) and a Certified Professional in Healthcare Information and Management Systems (CPHIMS).

Internal medicine is the medical specialty dealing with the prevention, diagnosis, and treatment of adult diseases. Physicians specializing in internal medicine are called internists. They manage and prevent common and complex diseases by providing comprehensive care and promoting overall well-being.

In addition to English, Dr. Fatima speaks Urdu and Hindi.

Learn More about Dr. Umbrine Fatima:

Through her findatopdoc profile, https://www.findatopdoc.com/doctor/81722926 or through My Health 360, https://myhealth360.net/pages/about-us

About FindaTopDoc.com

FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.

See the original post here:
Umbrine Fatima, MD, FACP, CPHIMS, an Internist with My Health 360 - York Pedia

Winter nights make joint pain worse and a snug comfortable bed with extra blankets will allow your pet to relax while theyre lying down and recuperating. Photo submitted.

While the cold weather may bring many positives such as TV series marathons in bed and an excuse to have just one more mug of hot chocolate, it unfortunately can also bring with it a lot of discomfort to our fur babies, said Hills Pet Nutrition.

According to Dr Guy Fyvie, Hills Pet Nutritions veterinary advisor, winter can exacerbate existing ailments, such as arthritis and, while we may be able to verbalise our pain, unfortunately our pets cant.

When it comes to cats its especially difficult for pet parents to acknowledge their pain as theyre absolute masters of disguise a survival instinct. Caused by the wear and tear of cartilage and bone of the joints, osteo-arthritis, if not managed properly can become extremely painful and debilitating.

He explained that pets are more likely to develop arthritis as they age, but at times it can occur in younger pets as a secondary ailment.

This could be due to an inherited disease such as hip or elbow dysplasia, or trauma to cartilage and ligaments.

He said according to the World Small Animal Veterinary Association (WSAVA) arthritis in pets is not a single type of problem and presents differently in the growing, versus the middle-aged, versus the older cat or dog.

Therefore, arthritis presenting at the different life stages requires a unique approach for optimal care. For example, in a growing dog surgical intervention may be the first line of treatment in an effort to limit the disease progression and the likelihood of pain in the future, whereas an older cat, for example, may require pain management and dietary changes.

We know arthritic cats hide their discomfort very well, so signs pet parents should look out for are sleeping all day, which contrary to popular belief isnt normal. Its called slowing down, and is almost always pain related. Also look out for a scruffier coat, especially around the tail area as they struggle to groom. Other signs are battling or being reluctant to jump, and having problems negotiating a high-sided cat litter box.

0828473906

0828473906

0828473906

Its not all doom and gloom, however. Dr. Fyvie said the good news is that there are plenty of things pet parents can do to reduce arthritis pain and improve their pets quality of life:

Weight management Carrying a little extra weight can become a significant load on your pets joints and can increase the inflammation, pain, and stress in an already arthritic pet. Maintaining optimum weight should be a priority. If your pets weight is a concern, make an appointment with your vet. Your vet will objectively assess their weight, recommend nutritional and lifestyle changes if necessary, and prescribe pain relief or anti-inflammatory medication, as required.

Regular exercise Its harder for all of us to get up and moving in winter, its just so cold. However, its important to maintain regular gentle exercise with our pets to keep their joints healthy and moving. A brisk walk with your dog when the winter sun is high, or a play session with your cat and an empty toilet roll will do wonders for everyones physical and mental well-being and is critical in the management of arthritis.

Comfortable bedding Make sure your pet has a warm and sheltered area that is out of the cold, wet and wind. Winter nights make joint pain worse and a snug comfortable bed with extra blankets will allow your pets to relax while theyre lying down and recuperating. Just make sure your pets bed isnt on a high level or is difficult to get in and out of, as this can put added pressure on their joints.

Avoid stairs For really arthritic pets, minimising access to stairs, where possible, can reduce unnecessary trauma. If stairs are unavoidable you may have to carry small pets up and down or use ramps around the house, if space allows. If jumping in and out of the car proves problematic for your larger dog, then consider a portable ramp to make this transition easier. For cats specifically, lower their food, water bowls and litter trays for easy access or, if this isnt possible, ensure there is a halfway jump to get up to them.

Anti-inflammatory medication Be sure to consult your vet for the correct pet medication cats especially do not tolerate human medicines, which can be fatal.

Nutrition The food your pet eats plays an important role in their overall health and well-being. For accurate diagnosis and treatment options, always consult your veterinarian and ask them to recommend the best food for your pets arthritis and joint health.

Read more:
Why our pets may be feeling the cold more than we think - Krugersdorp News

New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Personalized Medicine Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Personalized Medicine market.

The research study includes the latest updates about the COVID-19 impact on the Personalized Medicine sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Personalized Medicine manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Personalized Medicine market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Personalized Medicine sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Personalized Medicine, the report covers-

Bytype1

In Market Segmentation by Applications of the Personalized Medicine, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=3WN&utm_medium=002

The Personalized Medicine market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Personalized Medicine market.

This study analyzes the growth of Personalized Medicine based on the present, past and futuristic data and will render complete information about the Personalized Medicine industry to the market-leading industry players that will guide the direction of the Personalized Medicine market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Personalized Medicine market. Additionally, it includes a share of each segment of the Personalized Medicine market, giving methodical information about types and applications of the market.

Reasons for Buying Personalized Medicine Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Personalized Medicine market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=3WN&utm_medium=002

In the end, the Personalized Medicine market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Personalized Medicine market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Read the original:
Personalized Medicine Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 - 3rd Watch News

It is our aim to provide our readers with report for Personalized Medicines Market, which examines the industry during the period 2020 2026. One goal is to present deeper insight into this line of business in this document. The first part of the report focuses on providing the industry definition for the product or service under focus in the Personalized Medicines Market report. Next, the document will study the factors responsible for hindering and enhancing growth in the industry. After covering various areas of interest in the industry, the report aims to provide how the Personalized Medicines Market will grow during the forecast period.

The major vendors covered:

3G Biotech, Quest Diagnostics, Laboratory Corporation of America, Abbott, Agendia NV, Asuragen Inc, Becton Dickinson, CardioDx Inc., Foundation Medicine, Qiagen, Siemens Healthcare, Amgen, Bristol-Myers Squibb, GE Healthcare, Pfizer, Sanofi, 23andMe, Illumina. and more

The final report will add the analysis of the Impact of Covid-19 on Personalized Medicines Market.

Request a free sample copy @ https://www.reportsandmarkets.com/sample-request/global-personalized-medicines-market-report-2020?utm_source=jewishlifenews&utm_medium=38

The Personalized Medicines Market report between the years 2020 2026 will highlight the current value of the industry. At the same time, there is also an estimate of how much this line of business will be worth at the end of the forecast period. As it is our goal to maintain high levels of accuracy at all times, we will take a look at the CAGR of the Personalized Medicines Market. We make sure that all the information available in this report has excellent levels of readability. One way we achieve this target is by Personalized Medicines Market segmentation. Going through the report for 2020 2026 will bring our readers up-to-date regarding this industry.

While examining the information from this document, one thing becomes clear, the elements which contribute to increase in demand for the product or service. At the same time, there will be a focus on what drives the popularity of these types of products or services. This report is for those who want to learn about Personalized Medicines Market, along with its forecast for 2020 2026. Information regarding market revenue, competitive partners, and key players will also be available.

Segmentation

As discussed earlier, there is segmentation in the Personalized Medicines Market report, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Personalized Medicines Market. At the same time, there is emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Personalized Medicines Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of the Personalized Medicines Market report, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows Middle East and Africa, South and North America, Europe, and Asia Pacific. From the Personalized Medicines Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From this Personalized Medicines Market report, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Personalized Medicines Market report.

If you have any special requirements about this Personalized Medicines Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/global-personalized-medicines-market-report-2020?utm_source=jewishlifenews&utm_medium=38

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

See the rest here:
Impact of COVID-19 on Personalized Medicines 2020 Industry Growth, Size, Trends, Share, Opportunities and Forecast to 2026 - Jewish Life News